Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

8.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

737
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
737
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

12.2K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.2K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

287
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
287

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of Small-Molecule GLP‑1 Receptor Agonists with Improved Oral Pharmacokinetics Based on Orforglipron.

ACS medicinal chemistry letters·2026
Same author

Plasticizer-responsive molecular axes in heart failure: a subtype-aware toxicogenomic framework relevant to environmental health.

Environment international·2026
Same author

Multiscale machine learning molecular mechanics for mechanism and stereoselectivity of Diels-Alderase catalysis.

Nature communications·2026
Same author

Development and Test of Highly Accurate End Point Free Energy Methods. 4. Expanding Solvents Capability and logBB Prediction.

The journal of physical chemistry. B·2026
Same author

Clinical experiences of 109 children with foreign body ingestion: a retrospective study from Kunming, China.

Frontiers in pediatrics·2026
Same author

K16F/E22F Mutation Promotes Oligomerization and Alters β-Sheet Topology of Aβ16-22 Peptides: Insights from Molecular Dynamics Simulations.

ACS chemical neuroscience·2026

Related Experiment Video

Updated: Jul 13, 2025

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

13.8K

Discovery of Potent and Selective CB2 Agonists Utilizing a Function-Based Computational Screening Protocol.

Haixia Ge1, Beihong Ji2, Jiahui Fang3

  • 1School of Life Sciences, Huzhou University, Huzhou 313000, China.

ACS Chemical Neuroscience
|October 12, 2023
PubMed
Summary
This summary is machine-generated.

We developed a computational protocol using ligand-residue interaction profiles (LRIP) to design selective CB2 agonists. This method achieved a 70% success rate in identifying potent agonists and antagonists.

Keywords:
CB1/CB2function-based ligand designreceptor−ligand binding profilestructure−activity relationship

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.9K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

12.7K

Related Experiment Videos

Last Updated: Jul 13, 2025

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

13.8K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.9K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

12.7K

Area of Science:

  • Computational chemistry
  • Pharmacology
  • Drug design

Background:

  • Identifying selective agonists and antagonists is a significant challenge in computer-aided drug design.
  • The cannabinoid receptor 2 (CB2) is a key target for therapeutic interventions.

Purpose of the Study:

  • To develop a computational protocol for designing novel selective CB2 agonists.
  • To determine the agonist-antagonist function of compounds using ligand-residue interaction profiles (LRIP).

Main Methods:

  • Calculation of ligand-residue interaction profiles (LRIP).
  • Statistical analysis and free energy calculations to determine compound function.
  • Application of the protocol to CB2 agonist development, followed by in vitro functional assays.

Main Results:

  • A computational protocol was successfully applied to CB2 agonist development with a 70% success rate.
  • Potent CB2 agonists and antagonists showed distinct and overlapping interactions with key receptor residues.
  • Identified specific hotspot residues (e.g., I186 for agonists, L17 for antagonists) crucial for ligand binding.

Conclusions:

  • Ligand-residue interaction profile (LRIP) is a valuable concept for rational drug design.
  • The developed protocol enables the design of compounds with specific agonist or antagonist functions.
  • Identified novel hotspot residues that can guide future CB1/CB2 ligand design.